查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1566753

疼痛管理藥物市場：依藥物類別、適應症、疼痛類型：2024-2033 年全球機會分析與產業預測

Pain Management Drugs Market By Drug Class , By Indication By Pain Type : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 216 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

疼痛管理藥物市場

2023年疼痛管理藥物市場價值為726億美元，預計2024年至2033年複合年成長率為4.2%，到2033年達到1096億美元。

疼痛管理藥物是用於緩解疼痛的藥物，疼痛範圍從中度不適到重度疼痛。疼痛管理藥物配方由不同的藥物類別組成，例如鴉片類藥物、抗憂鬱症和乙醯胺酚。這些藥物針對不同類型的疼痛，包括肌肉骨骼疼痛、神經病變和發炎。疼痛管理藥物發揮作用的機制多種多樣，包括減少發炎、抑制神經系統中的疼痛訊號以及改變大腦化學物質以調節疼痛感知。

文明病和中風、心臟病、第二型糖尿病和癌症等慢性疾病的增加正在推動疼痛管理藥物市場的發展。此外，藥物製劑和給藥方法的進步，例如減少劑量數量的緩釋性，正在推動對藥物的需求，以提高患者的依從性和治療結果。最近，對奈米治療藥物的研究一直是市場的趨勢，因為奈米顆粒有望能夠精確定位目標並在低劑量下提供長期療效。

然而，疼痛治療藥物具有嚴重的副作用，如心血管事件、消化道出血、鎮靜、腎功能損害和呼吸抑制等，這限制了其消費量，並對市場擴張構成挑戰。為了消除傳統藥物的危險，人們正在考慮副作用較少的天然替代品。例如，卡痛葉（Kratom）是一種從帽柱樹（Mitragyna spiosa）中提取的草藥物質，被用作鴉片類藥物的替代品。卡痛藥已被證明在緩解纖維肌痛、關節炎和神經病變疼痛等慢性疼痛方面非常有效。

分部審查

疼痛管理藥物市場按藥物類別、適應症、疼痛類型和地區細分。依藥物類別分類，市場分為非類固醇消炎劑、麻醉劑、抗驚厥藥、抗偏頭痛藥、抗憂鬱症、鴉片類藥物和非麻醉性止痛藥。依適應症分為關節痛、神經病變疼痛、癌症疼痛、慢性背痛、術後疼痛、偏頭痛、纖維肌痛、肌肉拉傷/拉傷、骨折、急性闌尾炎等。依疼痛類型分為慢性疼痛和急性疼痛。從區域來看，分析涵蓋北美、歐洲、亞太地區和拉丁美洲/中東/非洲。

主要發現

按藥物類別分類，鴉片類藥物預計將在預測期內主導市場。

有跡象表明，到 2033 年，術後疼痛領域預計將成為最大股東。

按疼痛類型分類，預計慢性疼痛細分市場將在預測期內引領市場。

按地區分類，預計到 2033 年，北美地區的收益將最高。

該報告可以客製化。

  • 監管指引
  • 根據客戶興趣加入公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 擴大公司簡介列表
  • 歷史市場資料
  • 主要參與企業的詳細資料（Excel格式，包括位置、聯絡資訊、供應商/供應商網路等）

目錄

第1章簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 關鍵投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章疼痛管理藥物市場：依藥物類別

  • 市場概況
  • 非類固醇消炎劑
  • 麻醉劑
  • 抗驚厥藥
  • 抗偏頭痛藥
  • 抗憂鬱症
  • 鴉片類藥物
  • 非麻醉性止痛藥

第5章疼痛管理藥物市場：依適應症分類

  • 市場概況
  • 關節痛
  • 神經病變疼痛
  • 癌症痛
  • 慢性腰痛
  • 術後疼痛
  • 偏頭痛
  • 纖維肌痛
  • 肌肉扭傷/拉傷
  • 斷裂
  • 急性闌尾炎
  • 其他

第6章疼痛管理藥物市場：依疼痛類型

  • 市場概況
  • 慢性疼痛
  • 急性疼痛

第7章疼痛管理藥物市場：按地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國疼痛管理藥物市場
    • 加拿大疼痛管理藥物市場
    • 墨西哥止痛藥物市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 德國疼痛管理藥物市場
    • 法國止痛藥市場
    • 英國疼痛管理藥物市場
    • 義大利疼痛管理藥物市場
    • 西班牙止痛藥市場
    • 其他歐洲疼痛管理藥物市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 日本疼痛管理藥物市場
    • 中國疼痛管理藥物市場
    • 印度止痛藥市場
    • 澳洲疼痛管理藥物市場
    • 韓國疼痛管理藥物市場
    • 其他亞太地區止痛藥市場
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 巴西疼痛管理藥物市場
    • 沙烏地阿拉伯疼痛管理藥物市場
    • 南非疼痛管理藥物市場
    • 其他拉丁美洲/中東/非洲疼痛管理藥物市場

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2023年）

第9章 公司簡介

  • Novartis AG
  • Eli Lilly And Company
  • Abbott Laboratories
  • Endo Health Solutions, Inc.
  • Purdue Pharma LP
  • Pfizer, Inc.
  • Viatris Inc.
  • Merck And Co. Inc.
  • Johnson And Johnson
  • GlaxoSmithKline Plc
簡介目錄
Product Code: A00309

Pain Management Drugs Market

The pain management drugs market was valued at $72.6 billion in 2023 and is projected to reach $109.6 billion by 2033, growing at a CAGR of 4.2% from 2024 to 2033.

A pain management drug is medication prescribed for the alleviation of pain ranging from moderate discomfort to severe distress. The formulation of pain management drugs comprises of different drug class, including opioids, antidepressants or acetaminophen. These medications target diverse pain types, including musculoskeletal, neuropathic, and inflammatory pain. The mechanisms pertaining to the functioning of pain management drug are diverse such as lowering of inflammation, inhibition of pain signals in the nervous system, or alteration of brain chemistry to modulate the perception of pain.

Increase in the prevalence of lifestyle and chronic diseases such as stroke, heart disease, type II diabetes, and cancer is driving the pain management drugs market. In addition, advancements in drug formulations and delivery methods such as extended-release formulations with reduced dosing frequency are boosting the demand for the drugs as they enhance patient compliance & treatment outcomes. In recent times, explorations in nanotherapeutics are trending in the market as nanoparticles are anticipated to possess the capability of precisely identifying the target and offering long-term efficacy in significantly low dosage.

However, the severe side-effects of pain management drugs; including cardiovascular events, gastrointestinal bleeding, sedation, renal impairment, and respiratory depression; limit their consumption, hence presenting challenges for market expansion. To eliminate the hazards of conventional drugs, natural alternatives are being explored as they have potentially minimal to no side-effects. For instance, Kratom, a herbal substance obtained from the Mitragyna speciosa tree, is being utilized as an alternative to opioid drugs. Kratom medications have proved to be highly effective in providing relief from chronic pain conditions such as fibromyalgia & arthritis and neuropathic pain.

Segment Review

The pain management drugs market is segmented into drug class, indication, pain type, and region. On the basis of drug class, the market is divided into NSAIDs, anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and nonnarcotic analgesics. As per indication, it is classified into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, muscle sprain/strain, bone fracture, acute appendicitis, and others. By pain type, it is bifurcated into chronic pain and acute pain. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of drug class, the opioids segment is expected to dominate the market during the forecast period.

As per indication, the postoperative pain segment is predicted to be the highest shareholder by 2033.

By pain type, the chronic pain segment is anticipated to lead the market during the forecast period.

Region wise, North America is projected to be the highest revenue generator by 2033.

Competition Analysis

The major players operating in the global pain management drugs market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Endo Health Solutions, Inc., Purdue Pharma L.P., Pfizer, Inc., Viatris Inc., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Drug Class

  • NSAIDs
  • Anesthetics
  • Anticonvulsants
  • Anti-migraine Agents
  • Antidepressants
  • Opioids
  • Nonnarcotic Analgesics

By Indication

  • Arthritic Pain
  • Neuropathic Pain
  • Cancer Pain
  • Chronic Back Pain
  • Postoperative Pain
  • Migraine
  • Fibromyalgia
  • Muscle Sprain/Strain
  • Bone Fracture
  • Acute Appendicitis
  • Others

By Pain Type

  • Chronic Pain
  • Acute Pain

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Novartis AG
    • Eli Lilly & Company
    • Abbott Laboratories
    • Endo Health Solutions, Inc.
    • Purdue Pharma L.P.
    • Pfizer, Inc.
    • Viatris Inc.
    • Merck & Co. Inc.
    • Johnson & Johnson
    • GlaxoSmithKline Plc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Drug Class
  • 4.2. NSAIDs
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Anesthetics
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Anticonvulsants
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Anti-migraine Agents
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country
  • 4.6. Antidepressants
    • 4.6.1. Key Market Trends, Growth Factors and Opportunities
    • 4.6.2. Market Size and Forecast, By Region
    • 4.6.3. Market Share Analysis, By Country
  • 4.7. Opioids
    • 4.7.1. Key Market Trends, Growth Factors and Opportunities
    • 4.7.2. Market Size and Forecast, By Region
    • 4.7.3. Market Share Analysis, By Country
  • 4.8. Nonnarcotic Analgesics
    • 4.8.1. Key Market Trends, Growth Factors and Opportunities
    • 4.8.2. Market Size and Forecast, By Region
    • 4.8.3. Market Share Analysis, By Country

CHAPTER 5: PAIN MANAGEMENT DRUGS MARKET, BY INDICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Indication
  • 5.2. Arthritic Pain
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Neuropathic Pain
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Cancer Pain
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Chronic Back Pain
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country
  • 5.6. Postoperative Pain
    • 5.6.1. Key Market Trends, Growth Factors and Opportunities
    • 5.6.2. Market Size and Forecast, By Region
    • 5.6.3. Market Share Analysis, By Country
  • 5.7. Migraine
    • 5.7.1. Key Market Trends, Growth Factors and Opportunities
    • 5.7.2. Market Size and Forecast, By Region
    • 5.7.3. Market Share Analysis, By Country
  • 5.8. Fibromyalgia
    • 5.8.1. Key Market Trends, Growth Factors and Opportunities
    • 5.8.2. Market Size and Forecast, By Region
    • 5.8.3. Market Share Analysis, By Country
  • 5.9. Muscle Sprain/Strain
    • 5.9.1. Key Market Trends, Growth Factors and Opportunities
    • 5.9.2. Market Size and Forecast, By Region
    • 5.9.3. Market Share Analysis, By Country
  • 5.10. Bone Fracture
    • 5.10.1. Key Market Trends, Growth Factors and Opportunities
    • 5.10.2. Market Size and Forecast, By Region
    • 5.10.3. Market Share Analysis, By Country
  • 5.11. Acute Appendicitis
    • 5.11.1. Key Market Trends, Growth Factors and Opportunities
    • 5.11.2. Market Size and Forecast, By Region
    • 5.11.3. Market Share Analysis, By Country
  • 5.12. Others
    • 5.12.1. Key Market Trends, Growth Factors and Opportunities
    • 5.12.2. Market Size and Forecast, By Region
    • 5.12.3. Market Share Analysis, By Country

CHAPTER 6: PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Pain Type
  • 6.2. Chronic Pain
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Acute Pain
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country

CHAPTER 7: PAIN MANAGEMENT DRUGS MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Drug Class
    • 7.2.3. Market Size and Forecast, By Indication
    • 7.2.4. Market Size and Forecast, By Pain Type
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Pain Management Drugs Market
      • 7.2.6.1. Market Size and Forecast, By Drug Class
      • 7.2.6.2. Market Size and Forecast, By Indication
      • 7.2.6.3. Market Size and Forecast, By Pain Type
    • 7.2.7. Canada Pain Management Drugs Market
      • 7.2.7.1. Market Size and Forecast, By Drug Class
      • 7.2.7.2. Market Size and Forecast, By Indication
      • 7.2.7.3. Market Size and Forecast, By Pain Type
    • 7.2.8. Mexico Pain Management Drugs Market
      • 7.2.8.1. Market Size and Forecast, By Drug Class
      • 7.2.8.2. Market Size and Forecast, By Indication
      • 7.2.8.3. Market Size and Forecast, By Pain Type
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Drug Class
    • 7.3.3. Market Size and Forecast, By Indication
    • 7.3.4. Market Size and Forecast, By Pain Type
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. Germany Pain Management Drugs Market
      • 7.3.6.1. Market Size and Forecast, By Drug Class
      • 7.3.6.2. Market Size and Forecast, By Indication
      • 7.3.6.3. Market Size and Forecast, By Pain Type
    • 7.3.7. France Pain Management Drugs Market
      • 7.3.7.1. Market Size and Forecast, By Drug Class
      • 7.3.7.2. Market Size and Forecast, By Indication
      • 7.3.7.3. Market Size and Forecast, By Pain Type
    • 7.3.8. UK Pain Management Drugs Market
      • 7.3.8.1. Market Size and Forecast, By Drug Class
      • 7.3.8.2. Market Size and Forecast, By Indication
      • 7.3.8.3. Market Size and Forecast, By Pain Type
    • 7.3.9. Italy Pain Management Drugs Market
      • 7.3.9.1. Market Size and Forecast, By Drug Class
      • 7.3.9.2. Market Size and Forecast, By Indication
      • 7.3.9.3. Market Size and Forecast, By Pain Type
    • 7.3.10. Spain Pain Management Drugs Market
      • 7.3.10.1. Market Size and Forecast, By Drug Class
      • 7.3.10.2. Market Size and Forecast, By Indication
      • 7.3.10.3. Market Size and Forecast, By Pain Type
    • 7.3.11. Rest of Europe Pain Management Drugs Market
      • 7.3.11.1. Market Size and Forecast, By Drug Class
      • 7.3.11.2. Market Size and Forecast, By Indication
      • 7.3.11.3. Market Size and Forecast, By Pain Type
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Drug Class
    • 7.4.3. Market Size and Forecast, By Indication
    • 7.4.4. Market Size and Forecast, By Pain Type
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. Japan Pain Management Drugs Market
      • 7.4.6.1. Market Size and Forecast, By Drug Class
      • 7.4.6.2. Market Size and Forecast, By Indication
      • 7.4.6.3. Market Size and Forecast, By Pain Type
    • 7.4.7. China Pain Management Drugs Market
      • 7.4.7.1. Market Size and Forecast, By Drug Class
      • 7.4.7.2. Market Size and Forecast, By Indication
      • 7.4.7.3. Market Size and Forecast, By Pain Type
    • 7.4.8. India Pain Management Drugs Market
      • 7.4.8.1. Market Size and Forecast, By Drug Class
      • 7.4.8.2. Market Size and Forecast, By Indication
      • 7.4.8.3. Market Size and Forecast, By Pain Type
    • 7.4.9. Australia Pain Management Drugs Market
      • 7.4.9.1. Market Size and Forecast, By Drug Class
      • 7.4.9.2. Market Size and Forecast, By Indication
      • 7.4.9.3. Market Size and Forecast, By Pain Type
    • 7.4.10. South Korea Pain Management Drugs Market
      • 7.4.10.1. Market Size and Forecast, By Drug Class
      • 7.4.10.2. Market Size and Forecast, By Indication
      • 7.4.10.3. Market Size and Forecast, By Pain Type
    • 7.4.11. Rest of Asia-Pacific Pain Management Drugs Market
      • 7.4.11.1. Market Size and Forecast, By Drug Class
      • 7.4.11.2. Market Size and Forecast, By Indication
      • 7.4.11.3. Market Size and Forecast, By Pain Type
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Drug Class
    • 7.5.3. Market Size and Forecast, By Indication
    • 7.5.4. Market Size and Forecast, By Pain Type
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Pain Management Drugs Market
      • 7.5.6.1. Market Size and Forecast, By Drug Class
      • 7.5.6.2. Market Size and Forecast, By Indication
      • 7.5.6.3. Market Size and Forecast, By Pain Type
    • 7.5.7. Saudi Arabia Pain Management Drugs Market
      • 7.5.7.1. Market Size and Forecast, By Drug Class
      • 7.5.7.2. Market Size and Forecast, By Indication
      • 7.5.7.3. Market Size and Forecast, By Pain Type
    • 7.5.8. South Africa Pain Management Drugs Market
      • 7.5.8.1. Market Size and Forecast, By Drug Class
      • 7.5.8.2. Market Size and Forecast, By Indication
      • 7.5.8.3. Market Size and Forecast, By Pain Type
    • 7.5.9. Rest of LAMEA Pain Management Drugs Market
      • 7.5.9.1. Market Size and Forecast, By Drug Class
      • 7.5.9.2. Market Size and Forecast, By Indication
      • 7.5.9.3. Market Size and Forecast, By Pain Type

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Novartis AG
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Eli Lilly And Company
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Abbott Laboratories
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Endo Health Solutions, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Purdue Pharma L.P.
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Pfizer, Inc.
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Viatris Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Merck And Co. Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Johnson And Johnson
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. GlaxoSmithKline Plc
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments